WAVEMAN · COMPANY

QGEN · Qiagen N.V.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

QGEN

Name: QIAGEN N.V. (QGEN) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

QIAGEN N.V.

PHARMA & BIOTECH · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · CIK 0001015820

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

213

13F, latest reported quarter

REVENUE GROWTH

+5.7%

XBRL, annual

NET MARGIN

20.3%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

213 funds added or opened last quarter

more than 88% of Pharma & Biotech

REVENUE

+5.7% year over year

more than 55% of Pharma & Biotech

MARGIN

20.3% net margin

more than 89% of Pharma & Biotech

BUYBACKS

$280.1M repurchased, FY to 2025-12-31

more than 81% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

213 funds added or opened positions in the latest 13F quarter, of 340 holders.

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 213 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for QIAGEN N.V. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

WELLINGTON MANAGEMENT GROUP LLP

12,406,763.0 sh

$484.2M

PRINCIPAL FINANCIAL GROUP INC

6,648,681.0 sh

$260.0M

VANGUARD CAPITAL MANAGEMENT LLC

6,209,904.0 sh

$240.2M

BlackRock, Inc.

5,905,678.0 sh

$230.9M

MORGAN STANLEY

5,042,391.0 sh

$197.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Global X Genomics & Biotechnology ETF

$1.9M POSITION · AS OF 2026-02-28

3.6%

OAK HARVEST LONG/SHORT HEDGED EQUITY

$2.0M POSITION · AS OF 2026-02-28

2.1%

Invesco Biotechnology & Genome ETF

$5.0M POSITION · AS OF 2026-04-30

2.0%

ROBO Global Healthcare Technology and Innovation ETF

$673.3K POSITION · AS OF 2026-04-30

1.3%

JOHNSON OPPORTUNITY FUND

$1.9M POSITION · AS OF 2026-03-31

1.2%

Disciplined Value International Trust

$4.2M POSITION · AS OF 2026-03-31

1.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2025-07	2024-12	2023-12
REVENUE	$2.1B	—	$2.0B	$2.0B
GROSS PROFIT	$1.3B	—	$967.4M	$1.2B
OPERATING INCOME	$465.9M	—	$97.7M	$409.9M
NET INCOME	$424.9M	—	$83.6M	$341.3M
EPS (DILUTED)	1.94	—	0.37	1.48
OPERATING CASH FLOW	$654.3M	—	$673.6M	$459.5M
CASH	$839.0M	—	$663.6M	$668.1M
LONG-TERM DEBT	$1.7B	—	$839.7M	$921.8M
BUYBACKS	$280.1M	—	$292.1M	$0
DIVIDENDS PAID	$54.2M	$54.2M	$0	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE